Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
-
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
-
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
-
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
-
MYNZ Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
-
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
-
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
-
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
-
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
-
Mainz Biomed Enters into Technology Partnership with EDX Medical Group